Arena Pharmaceuticals (ARNA) 4.51 $ARNA Will Arena

New Post Public Reply Private Reply Replies (0) Message Board

Feb 28, 2015 at 7:28 PM

Arena Pharmaceuticals (ARNA) 4.51 $ARNA

Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 3:22PM CST
Arena Pharmaceuticals (ARNA) is scheduled to report fourth-quarter 2014 results on Mar 2.
AMRN: 1.51 (+0.05), PETX: 19.26 (+0.03), ARNA: 4.51 (-0.24)

Arena's Belviq Prescriptions Hold Up During Presidents' Day Holiday Week
Clinically Sound Investor - at Seeking Alpha - Fri Feb 27, 1:58PM CST

ARNA: 4.51 (-0.24)

Lessons From A Dozen Years Of Short Selling
Whitney Tilson - Seeking Alpha - Fri Feb 27, 9:39AM CST
(Editor's Note: Long-time contributor Whitney Tilson developed a presentation titled "Lessons from a Dozen Years of Short Selling" that he's presented at a handful of investment conferences in New York City. With his permission, we're now...
MBI: 9.00 (-0.04), FCEL: 1.31 (+0.06), HLF: 31.01 (-3.81), AFC: 25.59 (+0.14), VJET: 8.91 (+0.05), LL: 51.86 (+2.63), BLDP: 2.29 (-0.07), NSR: 26.52 (-0.14), TXTR: 28.21 (-0.48), RPTP: 9.27 (-0.37), LNKD: 267.20 (-3.56), ONVO: 5.92 (-0.14), XONE: 15.13 (-0.40), ARNA: 4.51 (-0.24), AGM: 31.94 (+0.35), PLUG: 3.08 (-0.03), FB: 78.97 (-1.44), DDD: 30.47 (+0.41), DECK: 74.24 (+0.50), TRIP: 89.25 (-0.61), CSLT: 7.29 (-0.21), LRN: 16.93 (unch), PCLN: 1,237.48 (-3.77), NFLX: 474.91 (-8.12), CROX: 11.15 (+0.46), CALL: 7.72 (+0.18), WRLD: 82.11 (-1.09), SODA: 17.92 (+0.66)

Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 34.94 (-0.30), CASM: 1.29 (+0.02), AMRN: 1.51 (+0.05), XON: 41.06 (-1.86), OSIR: 17.27 (-0.07), CPIX: 6.13 (+0.24), AMED: 30.17 (-0.73), CTIC: 2.34 (-0.04), INSY: 60.06 (-0.65), ECYT: 5.80 (-0.11), CMRX: 40.48 (-0.60), KYTH: 41.55 (-1.69), TRIB: 17.76 (-0.21), GALE: 1.80 (-0.03), ARNA: 4.51 (-0.24), XLRN: 40.63 (-0.37), ACRX: 8.86 (-0.10), ENDP: 85.60 (+0.36), DPLO: 30.00 (-0.09), SLXP: 157.20 (+0.25), PPHM: 1.41 (+0.03), MYL: 57.33 (+0.09), CBPO: 76.60 (-0.31), RGEN: 25.71 (-0.49), HALO: 15.07 (-0.21), ALIM: 5.23 (-0.05), ACHN: 12.14 (-0.35), GERN: 3.02 (-0.13), DARA: 0.99 (+0.05), SCMP: 15.38 (-0.62), ICPT: 221.37 (+2.30), CDXS: 3.53 (-0.02), PCRX: 114.77 (-1.22), PBYI: 213.01 (+7.05), FOLD: 8.76 (-0.03)

Orexigen's Q4 Results Disappoint, But Contrave Is Gaining Market Share
Kanak Kanti De - at Seeking Alpha - Thu Feb 26, 3:39PM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch
Brian Orelli, The Motley Fool - Motley Fool - Thu Feb 26, 6:02AM CST
The launch of Orexigen Therapeutics ' obesity drug Contrave was nothing to get too excited about. In the fourth quarter, which included 10 weeks of the launch, net sales of the drug were just $6.5 million, which resulted in $1.3 million in...
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Arena: Belviq Television Ads Resume After 1 Week Hiatus
Spencer Osborne - at Seeking Alpha - Tue Feb 24, 7:11AM CST

OREX: 5.64 (-0.23), ARNA: 4.51 (-0.24)

Orexigen: Contrave Scripts Pass 9,000 - Closing In On Qsymia
Spencer Osborne - at Seeking Alpha - Mon Feb 23, 10:00AM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Arena: Belviq Sales Show Modest Gain - Time To Assess 2015 Expectations?
Spencer Osborne - at Seeking Alpha - Mon Feb 23, 9:33AM CST

OREX: 5.64 (-0.23), NVO: 47.75 (+0.22), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Arena's Belviq Slows At A Bad Time
Clinically Sound Investor - at Seeking Alpha - Mon Feb 23, 8:57AM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus
at The Street - Fri Feb 20, 2:47PM CST
The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 0.94 (unch), AMRN: 1.51 (+0.05), HWAY: 22.38 (-0.37), HLS: 43.46 (-0.62), CYBX: 68.50 (+1.90), ESRX: 84.79 (+0.25), ECYT: 5.80 (-0.11), DXCM: 60.74 (-1.22), NSTG: 10.51 (-0.08), SRPT: 13.90 (+0.08), HZNP: 20.53 (+1.46), MDXG: 10.35 (-0.13), DEPO: 21.95 (-0.65), ANIK: 39.92 (-0.04), NKTR: 13.07 (+0.09), KERX: 12.16 (+0.23), ALIM: 5.23 (-0.05), EPZM: 23.52 (-0.08), AEGR: 27.20 (+0.20), MDRX: 12.01 (-0.74), ELGX: 15.77 (+0.09), NUVA: 45.75 (+0.76), HPTX: 29.55 (+1.82), GNMK: 12.71 (-0.19), MDVN: 117.53 (-2.21), HBIO: 5.46 (-0.09), ACAD: 37.97 (+0.19), ST: 53.74 (+0.09), RPTP: 9.27 (-0.37), FMI: 47.76 (-0.58), GMED: 24.28 (-0.78), JAZZ: 170.09 (-5.10), PTCT: 71.33 (-2.13), INFI: 15.20 (-0.84), ARNA: 4.51 (-0.24), EXEL: 2.93 (unch), NEO: 4.54 (+0.13), EXAS: 22.47 (-0.89), ALKS: 70.25 (-0.98), HTWR: 85.23 (-1.15), MNKD: 6.52 (-0.30), IPXL: 40.29 (-0.41), SQNM: 3.50 (-0.02), HALO: 15.07 (-0.21), ISIS: 68.56 (+1.23), CLVS: 76.46 (-1.43), BIO: 127.18 (+8.18), BIOS: 6.11 (+0.19), PCRX: 114.77 (-1.22)

Orexigen's Contrave Sales Recover - Investors Should Look To Europe
Spencer Osborne - at Seeking Alpha - Wed Feb 18, 11:02AM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Arena's Belviq Scripts Spike - Maintaining This Trajectory Important
Spencer Osborne - at Seeking Alpha - Wed Feb 18, 8:22AM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Arena Pharmaceuticals to Present at the 2015 RBC Capital Markets Healthcare Conference
PR Newswire - Wed Feb 18, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 2015 RBC Capital Markets Healthcare Conference on Tuesday, February 24, 2015, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time), at The New York Palace Hotel in New York City.
ARNA: 4.51 (-0.24)

Vivus' Qsymia Experiencing Both Prescription Growth And Market Share Erosion
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 7:03PM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Orexigen's Contrave Resumes Solid Growth Rate
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 7:45AM CST

OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Arena's Belviq Hits New High Prescription Mark, But Needs Similar Future Growth
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 7:42AM CST

ARNA: 4.51 (-0.24)

Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 102.51 (-0.29), OREX: 5.64 (-0.23), ECYT: 5.80 (-0.11), NVO: 47.75 (+0.22), MRK: 58.54 (-0.42), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)

Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.64 (-0.23), VRTX: 119.43 (-0.54), NVO: 47.75 (+0.22), VVUS: 2.61 (-0.08), QSII: 17.38 (-0.04), MDRX: 12.01 (-0.74), ARNA: 4.51 (-0.24)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greek-Serbian Ties Strengthen Ahead of EXPO 2027

Athens Networking Event: A Prelude to EXPO 2027 Buzzing with energy and the clinking of glasses, a meeting in Athens is doing what business folks love best—schmoozing and planning. Greek and Serbian representatives gathered up to lay the groundwork for EXPO 2027 Belgrade, and boy, was it all business. But hey, in our money-driven world, biz doesn't wait for Expo days to...

ZKONG, Hagebau Push ESLs in European Retail Revamp

ESLs: The Next Step in Retail Revamp Here’s the scoop: ZKONG and hagebau are making waves in the retail scene over in Germany. They’re bringing in Electronic Shelf Labels (ESLs) to kick traditional price tags to the curb. What started as a shake-up in supermarkets now rolls into the world of home improvement retail—headline by hagebaumarkt in Selb after nearly half...

Rockford Fosgate Elevates Marketing Maverick to Lead Role

Changing the Guard in High-Performance Audio Marketing Out of Arizona, we get a shake-up that feels like a no-brainer for anyone in the high-performance audio market. Rockford Fosgate decided to elevate Tammy Lowe to the Vice President of Marketing role, effective immediately. With nearly four decades under her belt at the sunny Tempe-based HQ, it's hard to argue with the...

Randi Cruz Steps Up as CFO at Bridge Legal

A Key Milestone for Bridge Legal Here's a juicy tidbit for you: Bridge Legal is shaking things up by promoting Randi Cruz to Chief Financial Officer. It's a big deal, folks, especially when you consider that this company is one of those movers and shakers in the legal tech world. Randi's journey at Bridge Legal hasn't been a walk in the park, but more of a strategic...

Innovative Sonar System Seeks to Simplify Fishing Boats

Navigating the Clutter on Fishing Boats You ever try setting up a sonar system on a fishing boat? It's like untangling a mess of Christmas lights. The cables, the hubs, the separate units—it’s chaos. Here's where a crafty inventor from Zumbro Falls, Minnesota, steps into the ring with an idea that's as refreshing as an ice-cold beer on a summer’s day: a centralized...

Geolava, Vaidio, Sensoneo Triumph in Texas Pitch Contest

North Texas Lights the Innovation Torch Big moves are happening in North Texas, with a pitch competition that's more than just smoke and mirrors. We're talking about an arena where regional challenges meet cutting-edge solutions, and out of a global mix, Geolava, Vaidio, and Sensoneo snagged the 2026 North Texas Connected Innovation Pitch Contest crown. It's high stakes...

Sodium-Ion Tech Showcased by Aeson Power in Melbourne

A Shock to the System: Sodium-Ion's Rising Star If you're tired of hearing about lithium, Aeson Power just gave us a much-needed jolt at All Energy Australia 2026. This isn't just some new fad—they've proven the real-world chops of sodium-ion technology across energy storage and automotive platforms. At the Melbourne show, they laid out their goods, showing how this...

Webull Faces Class Action: Investor Impact Deep Dive

What's Going On with Webull? Ah, Webull Corporation, you're in the hot seat now. If you blinked on October 7th, you might have missed a monumental 19.09% cliff dive in Webull's stock, tumbling down to a humble $5.89. The roar wasn't just the market reacting; it was the sonic boom of a class action lawsuit on their heels, alleging some slick legal sledding with misleading...

Xerox Faces Probes After $130M Profit Forecast Slash

When the Trust Breaks October 29, 2026 was a gut punch for Xerox investors. Watching the outlook dive by $130 million, the coffee-feeling in the trading rooms turned into something more bitter. A $105 million boost they once celebrated from tariff receivables now seems to be a fleeting shadow, as Xerox itself scuttles its adjusted operating income for 2026 to a range of...

Banco Santander's Troubles: Legal Heat on SAN

Brazilian Turbulence Shakes Banco Santander Imagine getting hit twice in a single week, once by a surprise election result and again by numbers that don't add up. That's the gut-wrenching scenario Banco Santander's (NYSE: SAN) investors are facing. After Brazil's unexpected election outcome, investor jitters translated into a 3.7% drop on October 26, 2026. Not two days...